Share Email Print
cover

Proceedings Paper

Optical detection of brain tumors using quantum dots
Author(s): Steven A. Toms; Hamid Daneshvar; Osman Muhammad; Heather Jackson; Michael A. Vogelbaum; Marcel Bruchez
Format Member Price Non-Member Price
PDF $14.40 $18.00
cover GOOD NEWS! Your organization subscribes to the SPIE Digital Library. You may be able to download this paper for free. Check Access

Paper Abstract

Introduction: Brain tumor margin detection remains a challenging problem in the operative resection of gliomas. A novel nanoparticle, a PEGylated quantum dot, has been shown to be phagocytized by macrophages in vivo. This feature may allow quantum dots to co-localize with brain tumors and serve as an optical aid in the surgical resection of brain tumors. Methods: Sprague-Daly rats were injected intracranially with C6 gliosarcoma cell lines to establish tumors. Two weeks after implantation of brain tumors, PEGylated quantum dots emitting at 705 nm (PEG-705 QD) were injected via the tail vein. Twenty-four hours post PEG-705 QD injection, the animals were sacrificed and their tissues examined. Results: PEGylated quantum dots are avidly phagocytized by macrophages and are taken up by liver, spleen and lymph nodes. Macrophages and microglia co-localize with glioma cells, carrying the optical nanoparticle, the quantum dot. Excitation of the PEG-705 quantum dots gives off a deep red fluorescence detectable with charge coupled device (CCD) cameras, optical spectroscopy units, and in dark field fluorescence microscopy. Conclusions: PEG-705QDs co-localize with brain tumors and may serve as an optical adjunct to aid in the operative resection of gliomas. The particles may be visualized in surgery with CCD cameras or detected by optical spectroscopy.

Paper Details

Date Published: 22 November 2005
PDF: 10 pages
Proc. SPIE 6009, Optical Methods in Drug Discovery and Development, 60090S (22 November 2005); doi: 10.1117/12.630724
Show Author Affiliations
Steven A. Toms, Brain Tumor Institute, The Cleveland Clinic Foundation (United States)
Hamid Daneshvar, Brain Tumor Institute, The Cleveland Clinic Foundation (United States)
Osman Muhammad, Brain Tumor Institute, The Cleveland Clinic Foundation (United States)
Heather Jackson, Brain Tumor Institute, The Cleveland Clinic Foundation (United States)
Michael A. Vogelbaum, Brain Tumor Institute, The Cleveland Clinic Foundation (United States)
Marcel Bruchez, Quantum Dot Corp. (United States)


Published in SPIE Proceedings Vol. 6009:
Optical Methods in Drug Discovery and Development
Mostafa Analoui; David A. Dunn, Editor(s)

© SPIE. Terms of Use
Back to Top